Navigation Links
Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
Date:9/28/2007

g, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.

For additional information, contact Protalix BioTherapeutics at: investors@protalix.com


'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Russell Killer Bids To Halt Publication Of Mental Health Report
2. China Doubles Its Investment In AIDS/HIV Treatment.
3. Biocon To Raise Its Investment In Scotland
4. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
5. Varicose Vein Treatments Turn Out To Be A Viable Health Investment
6. WHO calls for big investment in tests for TB
7. China Opens Doors For Foreign Investments In Hospitals Care System
8. Fidel Castro Appeals for Investment in Health Rather Than in Arms
9. No link between blood groups and prostate cancer
10. Consumer group seeks Sibutramine ban
11. Suicide risk high in 12-17 Age Group
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory 4Health News:FDA Warns Drug Makers to Stop Selling Unapproved Prescription Painkillers 2Health News:Don't Sacrifice Your Well-being in a Discount Destination 2Health News:Don't Sacrifice Your Well-being in a Discount Destination 3Health News:Frost & Sullivan: End-to-End Integration of HD Devices in the Operating Room Ushers in a New Era in Disruptive Technology 2Health News:Frost & Sullivan: End-to-End Integration of HD Devices in the Operating Room Ushers in a New Era in Disruptive Technology 3Health News:New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans 2Health News:New, Interactive Health Web Site Provides Information About a Painful and Often Debilitating Condition Affecting Older Americans 3
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards 5423 1Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards 5423 2Bob McDonald Outlines Key Long Term Growth Strategies To P 26amp 3BG Shareholders 5418 1Bob McDonald Outlines Key Long Term Growth Strategies To P 26amp 3BG Shareholders 5418 2Bob McDonald Outlines Key Long Term Growth Strategies To P 26amp 3BG Shareholders 5418 3Bob McDonald Outlines Key Long Term Growth Strategies To P 26amp 3BG Shareholders 5418 4Bob McDonald Outlines Key Long Term Growth Strategies To P 26amp 3BG Shareholders 5418 5Bob McDonald Outlines Key Long Term Growth Strategies To P 26amp 3BG Shareholders 5418 6Genetics of patterning the cerebral cortex 59356 1Genetics of patterning the cerebral cortex 59356 2Genetics of patterning the cerebral cortex 59356 3